Rilonacept
IL-1 decoy receptor (IL-1 Trap)
- Response rate
- Significant improvement vs placebo
- Onset
- Days–weeks
- Route
- SC 160mg load, then 80mg weekly
- Line
- 2nd
- IgM effect
- Improved
Evidence summary
Dimeric fusion protein acting as IL-1 'trap' neutralizing IL-1α and IL-1β. FDA-approved for FCAS and MWS (2008). Two sequential placebo-controlled studies demonstrated efficacy. Less widely used than anakinra/canakinumab due to limited long-term data and availability.
Sources (1)
I1Hoffman HM et al. (2008) Efficacy and safety of rilonacept in CAPS: results from two sequential placebo-controlled studies · Arthritis RheumPubMed ↗